Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585492 | 1.00 | FAAH (0.39) | FAAHPOLQCYP4F2CYP4A11RET | |
| SCHEMBL29585548 | 0.89 | FAAH (0.37) | FAAHPOLQCYP4F2CYP4A11RET | |
| SCHEMBL24424504 | 0.89 | FAAH (0.37) | FAAHPOLQCYP4F2CYP4A11RET | |
| SCHEMBL24424948 | 0.88 | FAAH (0.38) | FAAHPOLQCYP4F2CYP4A11RET | |
| SCHEMBL29243561 | 0.85 | FAAH (0.37) | FAAHRETKMT2A | |
| SCHEMBL6502716 | 0.82 | KMT2A (0.42) | FAAHCYP4F2CYP4A11KMT2AP2RY12 | |
| SCHEMBL29243581 | 0.81 | KMT2A (0.38) | FAAHKMT2AMGLL | |
| SCHEMBL14638395 | 0.81 | KMT2A (0.42) | FAAHCYP4F2CYP4A11KMT2AP2RY12 | |
| SCHEMBL20408354 | 0.80 | KMT2A (0.40) | FAAHCYP4F2CYP4A11KMT2AP2RY12 | |
| SCHEMBL24934371 | 0.80 | CYP4F2 (0.42) | FAAHCYP4F2CYP4A11KMT2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | FAAH 1251/4885POLQ 1065/4885CYP4F2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.